Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease Jul 18, 2018 5:27pm EDT
Emmaus Life Sciences Announces FDA Acceptance of IND Application for Clinical Study of L-glutamine for Treatment of Diverticulosis Jul 09, 2018 8:00am EDT
Sickle Cell Disease Association of America, Inc. Partners With Emmaus Life Sciences, Inc. Jun 19, 2018 8:00am EDT
Emmaus Life Sciences Announces Opening of Office in New York to Support Endari Launch Mar 26, 2018 8:00am EDT
Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for Sickle Cell Disease Treatment Xyndari (oral glutamine) Mar 12, 2018 8:00am EDT
Emmaus Life Sciences Announces Medicaid Coverage of Endari™ (L-glutamine oral powder) for Sickle Cell Disease in the United States Jan 29, 2018 8:00am EST
Emmaus Life Sciences Announces Availability of Endari™ (L-glutamine oral powder) for Sickle Cell Disease in the United States Jan 17, 2018 9:00am EST
Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency Dec 21, 2017 7:22pm EST
Emmaus Medical, Inc. Announces Availability of Endari™ for Treatment of Sickle Cell Disease Dec 11, 2017 9:00am EST
